NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
Novartis
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC